This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DGX Stock Gains Following the Launch of New AD-Detect Blood Test
by Zacks Equity Research
Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus
by Zacks Equity Research
ABT's Structural Heart, Rhythm Management and Neuromodulation businesses are likely to have driven its first-quarter 2025 performance.
Neogen Stock Tumbles on Q3 Earnings & Sales Miss, Margins Contract
by Zacks Equity Research
NEOG posts lower-than-expected earnings and revenues for the third quarter of fiscal 2025.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Should You Continue to Hold NVST Stock in Your Portfolio?
by Zacks Equity Research
Investors are optimistic about Envista, thanks to its strong momentum in the Specialty Products and Technologies segment.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
Telix Shares May Gain on the Distribution Deal With Cardinal Health
by Zacks Equity Research
TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
Is it the Right Time to Retain Labcorp Stock in Your Portfolio?
by Zacks Equity Research
LH's growth opportunities in important specialty testing areas are robust. Expanding through strategic acquisitions is an added plus.
Here's Why Masimo (MASI) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Walgreens Beats on Q2 Earnings, Withdraws Fiscal 2025 View, Stock Down
by Zacks Equity Research
WBA delivers better-than-expected earnings and revenues in the second quarter of fiscal 2025.
ICUI Stock Declines Despite Plans for Offsetting Tariff Impacts
by Zacks Equity Research
ICU Medical unveils a strategic plan to offset new U.S. tariffs, aiming to protect margins and stability amid medtech market volatility and global trade shifts.
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform
by Zacks Equity Research
GDRX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.
PODD Stock Benefits From the Launch of Omnipod 5 in Canada
by Zacks Equity Research
Insulet announces the commercial launch of Omnipod 5 AID system in Canada, with Dexcom G6 and G7 CGM sensor compatibility.
BD Seeks Potential Buyers for Life Sciences Business Division
by Zacks Equity Research
Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.
ZBH Stock to Gain From Volume Growth Amid Rising Costs
by Zacks Equity Research
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
GMED Stock May Benefit Following the Acquisition of Nevro
by Zacks Equity Research
Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back acquisitions & partnerships. A tough regulatory environment raises concerns.
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System
by Zacks Equity Research
Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.
RMD Stock Benefits From the Launch of NightOwl Across US
by Zacks Equity Research
Resmed launches NightOwl, an FDA-cleared home sleep apnea test, in the United States to diagnose OSA at home.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise investor optimism due to its strong product portfolio.
MCK Stock Gains as PRISM Acquisition Adds High-Growth Business
by Zacks Equity Research
McKesson acquires 80% ownership in PRISM Vision Holdings, diversifying its business into the high-growth area of ophthalmology. The deal is to be accretive this year.
Global Expansion in EPD and Innovations Support Abbott Stock
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Here's Why You Should Retain Integer Holdings Stock in Your Portfolio
by Zacks Equity Research
ITGR's research and product development activities raise optimism about the stock. Rising demand for its products bodes well for the company.